tiprankstipranks
Nanjing Leads Biolabs Co., Ltd. Class H (HK:9887)
:9887
Hong Kong Market
9887
Nanjing Leads Biolabs Co., Ltd. Class H
RESEARCH TOOLSreports
Want to see HK:9887 full AI Analyst Report?

Nanjing Leads Biolabs Co., Ltd. Class H (9887) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

9887 Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Nanjing
Leads Biolabs Co., Ltd. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

9887 Stock 12 Month Forecast

Average Price Target

HK$95.95
▲(4.29% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Nanjing Leads Biolabs Co., Ltd. Class H in the last 3 months. The average price target is HK$95.95 with a high forecast of HK$108.89 and a low forecast of HK$79.00. The average price target represents a 4.29% change from the last price of HK$92.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"48":"HK$48","109":"HK$109","63.25":"HK$63.3","78.5":"HK$78.5","93.75":"HK$93.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":108.89,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$108.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95.946,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$95.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$79.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[48,63.25,78.5,93.75,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.6,70.77615384615385,73.95230769230768,77.12846153846154,80.30461538461537,83.48076923076923,86.65692307692308,89.83307692307693,93.00923076923077,96.1853846153846,99.36153846153846,102.53769230769231,105.71384615384616,{"y":108.89,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.6,69.78046153846154,71.96092307692307,74.14138461538461,76.32184615384615,78.50230769230768,80.68276923076922,82.86323076923077,85.04369230769231,87.22415384615384,89.40461538461538,91.58507692307691,93.76553846153845,{"y":95.946,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,67.6,68.47692307692307,69.35384615384615,70.23076923076923,71.1076923076923,71.98461538461538,72.86153846153846,73.73846153846154,74.61538461538461,75.49230769230769,76.36923076923077,77.24615384615385,78.12307692307692,{"y":79,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":66.8,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.95,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.7,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.5,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.5,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.45,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.6,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.32,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.4,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.6,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$108.89Average Price TargetHK$95.95Lowest Price TargetHK$79.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CMB International Securities Analyst forecast on HK:9887
Andy Wang
CMB International Securities
Not Ranked
CMB International Securities
HK$100.5
Buy
9.24%
Upside
Reiterated
09/03/26
Leads Biolabs Initiated With Buy as Registrational LBL-024 Sets Path to 1H27 Approval and Pan-Tumor Growth
SDIC Securities Analyst forecast on HK:9887
Unknown Analyst
SDIC Securities
Not Ranked
SDIC Securities
HK$83.34
Buy
-9.41%
Downside
Reiterated
09/03/26
SDIC Securities Keeps Their Buy Rating on Nanjing Leads Biolabs Co., Ltd. Class H (9887)
Shenwan Hongyuan Analyst forecast on HK:9887
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$108.89
Buy
18.36%
Upside
Reiterated
08/21/26
Nanjing Leads Biolabs Co., Ltd. Class H (9887) Gets a Buy from Shenwan Hongyuan
Morgan Stanley Analyst forecast on HK:9887
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$62→HK$79
Hold
-14.13%
Downside
Reiterated
07/21/26
Nanjing Leads Biolabs Co., Ltd. Class H (9887) Gets a Hold from Morgan Stanley
CLSA Analyst forecast on HK:9887
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$108
Buy
17.39%
Upside
Reiterated
07/13/26
Nanjing Leads Biolabs Co., Ltd. Class H (9887) Receives a Buy from CLSA
GF Securities Analyst forecast on HK:9887
Unknown Analyst
GF Securities
Not Ranked
GF Securities
HK$110.96
Buy
20.61%
Upside
Reiterated
04/27/26
GF Securities Sticks to Its Buy Rating for Nanjing Leads Biolabs Co., Ltd. Class H (9887)
Orient Securities Analyst forecast on HK:9887
Unknown Analyst
Orient Securities
Not Ranked
Orient Securities
HK$81.01→HK$103.06
Buy
12.02%
Upside
Reiterated
04/21/26
Nanjing Leads Biolabs Co., Ltd. Class H (9887) Receives a Buy from Orient Securities
Huafu Securities Analyst forecast on HK:9887
Unknown Analyst
Huafu Securities
Not Ranked
Huafu Securities
HK$101.9→HK$140.75
Buy
52.99%
Upside
Reiterated
04/14/26
Huafu Securities Remains a Buy on Nanjing Leads Biolabs Co., Ltd. Class H (9887)
Citic Securities Analyst forecast on HK:9887
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$94
Buy
2.17%
Upside
Reiterated
12/01/25
Citic Securities Keeps Their Buy Rating on Nanjing Leads Biolabs Co., Ltd. Class H (9887)
Cinda International Research Limited Analyst forecast on HK:9887
Unknown Analyst
Cinda International Research Limited
Not Ranked
Cinda International Research Limited
HK$103.56
Buy
12.57%
Upside
Reiterated
11/02/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
CMB International Securities Analyst forecast on HK:9887
Andy Wang
CMB International Securities
Not Ranked
CMB International Securities
HK$100.5
Buy
9.24%
Upside
Reiterated
09/03/26
Leads Biolabs Initiated With Buy as Registrational LBL-024 Sets Path to 1H27 Approval and Pan-Tumor Growth
SDIC Securities Analyst forecast on HK:9887
Unknown Analyst
SDIC Securities
Not Ranked
SDIC Securities
HK$83.34
Buy
-9.41%
Downside
Reiterated
09/03/26
SDIC Securities Keeps Their Buy Rating on Nanjing Leads Biolabs Co., Ltd. Class H (9887)
Shenwan Hongyuan Analyst forecast on HK:9887
Unknown Analyst
Shenwan Hongyuan
Not Ranked
Shenwan Hongyuan
HK$108.89
Buy
18.36%
Upside
Reiterated
08/21/26
Nanjing Leads Biolabs Co., Ltd. Class H (9887) Gets a Buy from Shenwan Hongyuan
Morgan Stanley Analyst forecast on HK:9887
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$62→HK$79
Hold
-14.13%
Downside
Reiterated
07/21/26
Nanjing Leads Biolabs Co., Ltd. Class H (9887) Gets a Hold from Morgan Stanley
CLSA Analyst forecast on HK:9887
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$108
Buy
17.39%
Upside
Reiterated
07/13/26
Nanjing Leads Biolabs Co., Ltd. Class H (9887) Receives a Buy from CLSA
GF Securities Analyst forecast on HK:9887
Unknown Analyst
GF Securities
Not Ranked
GF Securities
HK$110.96
Buy
20.61%
Upside
Reiterated
04/27/26
GF Securities Sticks to Its Buy Rating for Nanjing Leads Biolabs Co., Ltd. Class H (9887)
Orient Securities Analyst forecast on HK:9887
Unknown Analyst
Orient Securities
Not Ranked
Orient Securities
HK$81.01→HK$103.06
Buy
12.02%
Upside
Reiterated
04/21/26
Nanjing Leads Biolabs Co., Ltd. Class H (9887) Receives a Buy from Orient Securities
Huafu Securities Analyst forecast on HK:9887
Unknown Analyst
Huafu Securities
Not Ranked
Huafu Securities
HK$101.9→HK$140.75
Buy
52.99%
Upside
Reiterated
04/14/26
Huafu Securities Remains a Buy on Nanjing Leads Biolabs Co., Ltd. Class H (9887)
Citic Securities Analyst forecast on HK:9887
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
HK$94
Buy
2.17%
Upside
Reiterated
12/01/25
Citic Securities Keeps Their Buy Rating on Nanjing Leads Biolabs Co., Ltd. Class H (9887)
Cinda International Research Limited Analyst forecast on HK:9887
Unknown Analyst
Cinda International Research Limited
Not Ranked
Cinda International Research Limited
HK$103.56
Buy
12.57%
Upside
Reiterated
11/02/25
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nanjing Leads Biolabs Co., Ltd. Class H

3 Months
Andy WangCMB International Securities
Success Rate
0/2 ratings generated profit
0%
Average Return
-19.35%
Copying Andy Wang's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -19.35% per trade.
1 Year
Andy WangCMB International Securities
Success Rate
0/2 ratings generated profit
0%
Average Return
-9.45%
Copying Andy Wang's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -9.45% per trade.
2 Years
Andy WangCMB International Securities
Success Rate
0/2 ratings generated profit
0%
Average Return
-9.45%
Copying Andy Wang's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -9.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

9887 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
1
1
2
2
Buy
5
2
0
0
2
Hold
1
1
2
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
4
3
3
5
In the current month, 9887 has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 9887 average Analyst price target in the past 3 months is 95.95.
Each month's total comprises the sum of three months' worth of ratings.

9887 Financial Forecast

9887 Earnings Forecast

The previous quarter’s earnings for 9887 were -HK$0.25.
The previous quarter’s earnings for 9887 were -HK$0.25.

9887 Sales Forecast

The previous quarter’s earnings for 9887 were HK$194.05M.
The previous quarter’s earnings for 9887 were HK$194.05M.

9887 Stock Forecast FAQ

What is HK:9887’s average 12-month price target, according to analysts?
Based on analyst ratings, Nanjing Leads Biolabs Co., Ltd. Class H’s 12-month average price target is 95.95.
    What is HK:9887’s upside potential, based on the analysts’ average price target?
    Nanjing Leads Biolabs Co., Ltd. Class H has 4.29% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Nanjing Leads Biolabs Co., Ltd. Class H a Buy, Sell or Hold?
          Nanjing Leads Biolabs Co., Ltd. Class H has a consensus rating of Strong Buy, which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Nanjing Leads Biolabs Co., Ltd. Class H’s share price target?
            The average share price target for Nanjing Leads Biolabs Co., Ltd. Class H is 95.95. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$108.89 ,and the lowest forecast is HK$79.00. The average share price target represents 4.29% Increase from the current price of HK$92.
              What do analysts say about Nanjing Leads Biolabs Co., Ltd. Class H?
              Nanjing Leads Biolabs Co., Ltd. Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of Nanjing Leads Biolabs Co., Ltd. Class H?
                To buy shares of HK:9887, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.